Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/133456
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Torres Martí, Antoni | - |
dc.contributor.author | Motos, Ana | - |
dc.contributor.author | Battaglini, Denise | - |
dc.contributor.author | Bassi, Gianluigi Li | - |
dc.date.accessioned | 2019-05-20T14:12:21Z | - |
dc.date.available | 2019-05-20T14:12:21Z | - |
dc.date.issued | 2018-12-17 | - |
dc.identifier.issn | 1364-8535 | - |
dc.identifier.uri | http://hdl.handle.net/2445/133456 | - |
dc.description.abstract | Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials. | - |
dc.format.extent | 6 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | BioMed Central | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1186/s13054-018-1958-4 | - |
dc.relation.ispartof | Critical Care, 2018, vol. 22, num. 1, p. 343 | - |
dc.relation.uri | https://doi.org/10.1186/s13054-018-1958-4 | - |
dc.rights | cc-by (c) Torres Martí, Antoni et al., 2018 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | Bacteris gramnegatius | - |
dc.subject.classification | Unitats de cures intensives | - |
dc.subject.classification | Infeccions respiratòries | - |
dc.subject.other | Gram-negative bacteria | - |
dc.subject.other | Intensive care units | - |
dc.subject.other | Respiratory infections | - |
dc.title | Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 686795 | - |
dc.date.updated | 2019-05-20T14:12:21Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 30558658 | - |
Appears in Collections: | Articles publicats en revistes (Medicina) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
686795.pdf | 2.7 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License